Latest Entremed Inc (ENMD) Headlines 2014 Most
Post# of 30
Posted On: 03/13/2014 8:04:30 AM
Latest Entremed Inc (ENMD) Headlines
2014 Most Athletic Pests
PR Newswire - Thu Jan 23, 5:00AM CST
World-class athletes competing on behalf of their countries are the epitome of must-see TV to the American public. As our USA athletes prepare to vie for gold this winter, Arrow Exterminators has prepared a list of the top five Most Athletic Pests to honor insects that possess Olympic-worthy traits designed by nature. To view the infographic: http://www.arrowexterminators.com/media/13613...0Pests.jpg
EntreMed Files New Drug Global Clinical Trial Application For ENMD-2076 With China CFDA
PR Newswire - Mon Jan 13, 6:00AM CST
EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of diseases, announced today that it has moved to expand its Phase 2 clinical trial for its drug candidate ENMD-2076 in advanced ovarian clear cell carcinoma (OCCC) with the submission of a new drug global clinical trial application with China's Food and Drug Administration (CFDA). The ongoing Phase 2 trial is currently being conducted at Princess Margaret Cancer Centre in Toronto, along with participation from up to seven additional cancer centers in Canada and the U.S.
Seed Hawk Receives Carbon Footprint Certification
PR Newswire - Tue Jan 07, 9:00AM CST
Seed Hawk Inc. has become the first agricultural equipment company in the world to receive Carbon Trust carbon footprint certification. This certification communicates Seed Hawk's achievements in accurately measuring the carbon footprint for their products.
EntreMed Reports Third Quarter 2013 Financial Results
PR Newswire - Thu Nov 14, 6:00AM CST
EntreMed, Inc. (NASDAQ: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers, today reported financial results for the three and nine-month periods ending September 30, 2013.
EntreMed Commences Phase 2 Trial For ENMD-2076 In Ovarian Clear Cell Carcinomas
PR Newswire - Thu Oct 31, 6:00AM CDT
EntreMed, Inc. (NASDAQ: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers, announced today the commencement of a multi-center Phase 2 study entitled "Phase II Study of Oral ENMD-2076 Administered to Patients with Ovarian Clear Cell Carcinomas." The study is led by principal investigator Amit M. Oza, MD at Princess Margaret Cancer Centre in Toronto, Canada with participation of up to seven additional cancer centers in Canada and the United States. More information about the clinical trial can be found at www.clinicaltrials.gov.
Data Presented For ENMD-2076 In Xenograft Models Of Human Hepatocellular Carcinoma
PR Newswire - Tue Oct 22, 12:00PM CDT
EntreMed, Inc. (NASDAQ: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers, announced today the presentation of preclinical data for a study comparing the efficacy of ENMD-2076 against that of standard of care agents including sorafenib, doxorubicin, and 5-FU for human hepatocellular carcinoma (HCC) models. The results of the study were presented at AACR-NCI-EORTC International Conference being held this week in Boston, Massachusetts.
Data Presented For ENMD-2076 In Preclinical Models Of Triple-Negative Breast Cancer
PR Newswire - Mon Oct 21, 6:00AM CDT
EntreMed, Inc. (NASDAQ:ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers, announced today the presentation of preclinical data from a study to assess the role of p53 family tumor suppressors in mediating response to ENMD-2076 in triple-negative breast cancer (TNBC). The study was led by Dr. Jennifer R. Diamond of University of Colorado and the results were presented at the AACR-NCI-EORTC International Conference being held this week in Boston, Massachusetts.
EntreMed Reports Second Quarter 2013 Financial Results
PR Newswire - Wed Aug 14, 6:00AM CDT
EntreMed, Inc. (NASDAQ: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers, today reported financial results for the three and six-month periods ended June 30, 2013.
EntreMed Initiates Crossover Bioavailability And Food Effect Study Of ENMD-2076 Dosage Form To Be Used For Pivotal/Registration Clinical Trials
PR Newswire - Mon Jul 29, 6:00AM CDT
EntreMed, Inc. (NASDAQ: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers, announced today that it has initiated a crossover bioavailability and food effect study of ENMD-2076. The study is a single-blind, randomized, single-dose, crossover study with a food effect arm to investigate the safety and relative bioavailability of two dosage forms of ENMD-2076 administered as escalating doses in two cohorts of healthy subjects. The study is expected to enroll approximately 29 healthy adult volunteers and will be conducted in Tempe, Arizona by a clinical research organization. EntreMed anticipates the clinical portion of the study will be completed by year end, and that pharmacokinetic analysis will be completed in early 2014.
ENMD, CRI, CTRP, OVRL, KWK, ABAX Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Thu Jul 04, 5:00AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Entremed Inc (NASDAQ:ENMD), Carter's Inc (NYSE:CRI), Ctrip.Com International Ltd (NASDAQ:CTRP), Overland Storage Inc (NASDAQ:OVRL), Quicksilver Resources Inc (NYSE:KWK), Abaxis Inc (NASDAQ:ABAX) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
EntreMed Files New Drug Global Clinical Trial Application For ENMD-2076 With China CFDA To Expand Clinical Trial For Advanced/Metastatic Sarcoma
PR Newswire - Thu Jun 27, 6:00AM CDT
EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers, announced today that it has submitted a new drug global clinical trial application with the China Food and Drug Administration (CFDA) for its proprietary oncology drug candidate, ENMD-2076. The purpose of the application is to expand the Company's Phase 2 clinical trial in advanced/metastatic sarcoma which currently is being conducted at Princess Margaret Hospital. This submission is the Company's second new drug global clinical trial application with the CFDA. The first application when approved will expand the Company's Phase 2 clinical trial for triple-negative breast cancer which currently is being conducted at the University of Colorado and Indiana University. More information about the clinical trials can be found at www.clinicaltrials.gov.
DARA, AAU, GPRE, BVSN, SMSI, ENMD Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Tue Jun 04, 5:17AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of DARA Biosciences Inc (NASDAQ
ARA), ALMADEN MINERALS LTD (AMEX:AAU), Green Plains Renewable Energy Inc (NASDAQ:GPRE), BroadVision Inc (NASDAQ:BVSN), Smith Micro Software Inc (NASDAQ:SMSI), Entremed Inc (NASDAQ:ENMD) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
EntreMed Reports First Quarter 2013 Financial Results
PR Newswire - Wed May 15, 6:00AM CDT
EntreMed, Inc. (NASDAQ: ENMD), a clinical-stage pharmaceutical company, today reported financial results for the three months ended March 31, 2013.
Patent Issued In U.S. For EntreMed's 2ME2 In Rheumatoid Diseases
PR Newswire - Fri May 03, 6:00AM CDT
EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers, announced the issuance of a U.S. patent covering methods of treatment and formulations for its clinical-stage compound, 2-methoxyestradiol (2ME2).
EntreMed Announces Changes to Board of Directors and CEO Appointment
PR Newswire - Fri Apr 05, 6:00AM CDT
EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, announced today that its Board of Directors has appointed two new individuals as directors. Joining the Board are James Huang and Y. Alexander Wu, Ph.D.
EntreMed Reports Fourth Quarter And Year-End 2012 Financial Results And Business Outlook For 2013
PR Newswire - Thu Mar 21, 6:00AM CDT
EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, today reported results for the three months and twelve months ended December 31, 2012.
WEALTHMAKERS.COM Issues Bullish Research Reports on CHDN, CSFL, DDR, DORM, DRD, ENMD
M2 - Mon Mar 18, 11:18AM CDT
WEALTHMAKERS.COM / www.wealthmakers.com , a Wall Street research and trading firm providing unbiased statistical stock market predictions to empower investors, securities professionals and public company employees to make precise, predictive and profitable trading decisions, has issued new research reports today on the following stocks: Churchill Downs Inc (NASDAQ:CHDN), Centerstate Banks Inc (NASDAQ:CSFL), DDR Corp (NYSE DR), Dorman Products Inc (NASDAQ ORM), DRDGOLD Ltd (NYSE RD), Entremed Inc (NASDAQ:ENMD)
Burrill Securities Inc plans USD10.7m of securities in a registered direct offering, with Burrill Securities LLC as exclusive placement agent
M2 - Mon Mar 04, 7:06AM CST
Pharmaceutical company EntreMed Inc (NASDAQ:ENMD) reported on Friday the receipt of commitments from investors to purchase about USD10.7m of securities in a registered direct offering.
Burrill Securities Acts as Exclusive Placement Agent for EntreMed $10.7 Million Registered Direct
Marketwire - Fri Mar 01, 3:32PM CST
EntreMed, Inc. (NASDAQ: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, announced today that it has received commitments from investors, including institutional investors Kleiner Perkins Caufield Byers China Fund II, L.P. and IDG-Accel China Growth Fund III L.P. to purchase approximately $10.7 million of securities in a registered direct offering. Burrill Securities LLC acted as exclusive placement agent in this transaction.
EntreMed To Raise $10.7 Million In Registered Direct Offering
PR Newswire - Fri Mar 01, 7:30AM CST
EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, announced today that it has received commitments from investors, including institutional investors Kleiner Perkins Caufield Byers China Fund II, L.P. and IDG-Accel China Growth Fund III L.P. to purchase approximately $10.7 million of securities in a registered direct offering. EntreMed expects to receive net proceeds of approximately $10.3 million after deducting agent's fees and other offering expenses. EntreMed has agreed to sell an aggregate of 4,495,833 shares of its common stock and warrants to purchase 2,247,917 shares of its common stock. Each unit, consisting of one share of common stock and a warrant to purchase 0.5 share of common stock will be sold for a purchase price of $2.40. The warrants will become exercisable 181 days after the closing and have a term of three years and an exercise price equal to the market value per share of common stock on February 28, 2013. The
2014 Most Athletic Pests
PR Newswire - Thu Jan 23, 5:00AM CST
World-class athletes competing on behalf of their countries are the epitome of must-see TV to the American public. As our USA athletes prepare to vie for gold this winter, Arrow Exterminators has prepared a list of the top five Most Athletic Pests to honor insects that possess Olympic-worthy traits designed by nature. To view the infographic: http://www.arrowexterminators.com/media/13613...0Pests.jpg
EntreMed Files New Drug Global Clinical Trial Application For ENMD-2076 With China CFDA
PR Newswire - Mon Jan 13, 6:00AM CST
EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of diseases, announced today that it has moved to expand its Phase 2 clinical trial for its drug candidate ENMD-2076 in advanced ovarian clear cell carcinoma (OCCC) with the submission of a new drug global clinical trial application with China's Food and Drug Administration (CFDA). The ongoing Phase 2 trial is currently being conducted at Princess Margaret Cancer Centre in Toronto, along with participation from up to seven additional cancer centers in Canada and the U.S.
Seed Hawk Receives Carbon Footprint Certification
PR Newswire - Tue Jan 07, 9:00AM CST
Seed Hawk Inc. has become the first agricultural equipment company in the world to receive Carbon Trust carbon footprint certification. This certification communicates Seed Hawk's achievements in accurately measuring the carbon footprint for their products.
EntreMed Reports Third Quarter 2013 Financial Results
PR Newswire - Thu Nov 14, 6:00AM CST
EntreMed, Inc. (NASDAQ: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers, today reported financial results for the three and nine-month periods ending September 30, 2013.
EntreMed Commences Phase 2 Trial For ENMD-2076 In Ovarian Clear Cell Carcinomas
PR Newswire - Thu Oct 31, 6:00AM CDT
EntreMed, Inc. (NASDAQ: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers, announced today the commencement of a multi-center Phase 2 study entitled "Phase II Study of Oral ENMD-2076 Administered to Patients with Ovarian Clear Cell Carcinomas." The study is led by principal investigator Amit M. Oza, MD at Princess Margaret Cancer Centre in Toronto, Canada with participation of up to seven additional cancer centers in Canada and the United States. More information about the clinical trial can be found at www.clinicaltrials.gov.
Data Presented For ENMD-2076 In Xenograft Models Of Human Hepatocellular Carcinoma
PR Newswire - Tue Oct 22, 12:00PM CDT
EntreMed, Inc. (NASDAQ: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers, announced today the presentation of preclinical data for a study comparing the efficacy of ENMD-2076 against that of standard of care agents including sorafenib, doxorubicin, and 5-FU for human hepatocellular carcinoma (HCC) models. The results of the study were presented at AACR-NCI-EORTC International Conference being held this week in Boston, Massachusetts.
Data Presented For ENMD-2076 In Preclinical Models Of Triple-Negative Breast Cancer
PR Newswire - Mon Oct 21, 6:00AM CDT
EntreMed, Inc. (NASDAQ:ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers, announced today the presentation of preclinical data from a study to assess the role of p53 family tumor suppressors in mediating response to ENMD-2076 in triple-negative breast cancer (TNBC). The study was led by Dr. Jennifer R. Diamond of University of Colorado and the results were presented at the AACR-NCI-EORTC International Conference being held this week in Boston, Massachusetts.
EntreMed Reports Second Quarter 2013 Financial Results
PR Newswire - Wed Aug 14, 6:00AM CDT
EntreMed, Inc. (NASDAQ: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers, today reported financial results for the three and six-month periods ended June 30, 2013.
EntreMed Initiates Crossover Bioavailability And Food Effect Study Of ENMD-2076 Dosage Form To Be Used For Pivotal/Registration Clinical Trials
PR Newswire - Mon Jul 29, 6:00AM CDT
EntreMed, Inc. (NASDAQ: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers, announced today that it has initiated a crossover bioavailability and food effect study of ENMD-2076. The study is a single-blind, randomized, single-dose, crossover study with a food effect arm to investigate the safety and relative bioavailability of two dosage forms of ENMD-2076 administered as escalating doses in two cohorts of healthy subjects. The study is expected to enroll approximately 29 healthy adult volunteers and will be conducted in Tempe, Arizona by a clinical research organization. EntreMed anticipates the clinical portion of the study will be completed by year end, and that pharmacokinetic analysis will be completed in early 2014.
ENMD, CRI, CTRP, OVRL, KWK, ABAX Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Thu Jul 04, 5:00AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Entremed Inc (NASDAQ:ENMD), Carter's Inc (NYSE:CRI), Ctrip.Com International Ltd (NASDAQ:CTRP), Overland Storage Inc (NASDAQ:OVRL), Quicksilver Resources Inc (NYSE:KWK), Abaxis Inc (NASDAQ:ABAX) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
EntreMed Files New Drug Global Clinical Trial Application For ENMD-2076 With China CFDA To Expand Clinical Trial For Advanced/Metastatic Sarcoma
PR Newswire - Thu Jun 27, 6:00AM CDT
EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers, announced today that it has submitted a new drug global clinical trial application with the China Food and Drug Administration (CFDA) for its proprietary oncology drug candidate, ENMD-2076. The purpose of the application is to expand the Company's Phase 2 clinical trial in advanced/metastatic sarcoma which currently is being conducted at Princess Margaret Hospital. This submission is the Company's second new drug global clinical trial application with the CFDA. The first application when approved will expand the Company's Phase 2 clinical trial for triple-negative breast cancer which currently is being conducted at the University of Colorado and Indiana University. More information about the clinical trials can be found at www.clinicaltrials.gov.
DARA, AAU, GPRE, BVSN, SMSI, ENMD Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Tue Jun 04, 5:17AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of DARA Biosciences Inc (NASDAQ
ARA), ALMADEN MINERALS LTD (AMEX:AAU), Green Plains Renewable Energy Inc (NASDAQ:GPRE), BroadVision Inc (NASDAQ:BVSN), Smith Micro Software Inc (NASDAQ:SMSI), Entremed Inc (NASDAQ:ENMD) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: EntreMed Reports First Quarter 2013 Financial Results
PR Newswire - Wed May 15, 6:00AM CDT
EntreMed, Inc. (NASDAQ: ENMD), a clinical-stage pharmaceutical company, today reported financial results for the three months ended March 31, 2013.
Patent Issued In U.S. For EntreMed's 2ME2 In Rheumatoid Diseases
PR Newswire - Fri May 03, 6:00AM CDT
EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers, announced the issuance of a U.S. patent covering methods of treatment and formulations for its clinical-stage compound, 2-methoxyestradiol (2ME2).
EntreMed Announces Changes to Board of Directors and CEO Appointment
PR Newswire - Fri Apr 05, 6:00AM CDT
EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, announced today that its Board of Directors has appointed two new individuals as directors. Joining the Board are James Huang and Y. Alexander Wu, Ph.D.
EntreMed Reports Fourth Quarter And Year-End 2012 Financial Results And Business Outlook For 2013
PR Newswire - Thu Mar 21, 6:00AM CDT
EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, today reported results for the three months and twelve months ended December 31, 2012.
WEALTHMAKERS.COM Issues Bullish Research Reports on CHDN, CSFL, DDR, DORM, DRD, ENMD
M2 - Mon Mar 18, 11:18AM CDT
WEALTHMAKERS.COM / www.wealthmakers.com , a Wall Street research and trading firm providing unbiased statistical stock market predictions to empower investors, securities professionals and public company employees to make precise, predictive and profitable trading decisions, has issued new research reports today on the following stocks: Churchill Downs Inc (NASDAQ:CHDN), Centerstate Banks Inc (NASDAQ:CSFL), DDR Corp (NYSE
DR), Dorman Products Inc (NASDAQ ORM), DRDGOLD Ltd (NYSE RD), Entremed Inc (NASDAQ:ENMD) Burrill Securities Inc plans USD10.7m of securities in a registered direct offering, with Burrill Securities LLC as exclusive placement agent
M2 - Mon Mar 04, 7:06AM CST
Pharmaceutical company EntreMed Inc (NASDAQ:ENMD) reported on Friday the receipt of commitments from investors to purchase about USD10.7m of securities in a registered direct offering.
Burrill Securities Acts as Exclusive Placement Agent for EntreMed $10.7 Million Registered Direct
Marketwire - Fri Mar 01, 3:32PM CST
EntreMed, Inc. (NASDAQ: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, announced today that it has received commitments from investors, including institutional investors Kleiner Perkins Caufield Byers China Fund II, L.P. and IDG-Accel China Growth Fund III L.P. to purchase approximately $10.7 million of securities in a registered direct offering. Burrill Securities LLC acted as exclusive placement agent in this transaction.
EntreMed To Raise $10.7 Million In Registered Direct Offering
PR Newswire - Fri Mar 01, 7:30AM CST
EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, announced today that it has received commitments from investors, including institutional investors Kleiner Perkins Caufield Byers China Fund II, L.P. and IDG-Accel China Growth Fund III L.P. to purchase approximately $10.7 million of securities in a registered direct offering. EntreMed expects to receive net proceeds of approximately $10.3 million after deducting agent's fees and other offering expenses. EntreMed has agreed to sell an aggregate of 4,495,833 shares of its common stock and warrants to purchase 2,247,917 shares of its common stock. Each unit, consisting of one share of common stock and a warrant to purchase 0.5 share of common stock will be sold for a purchase price of $2.40. The warrants will become exercisable 181 days after the closing and have a term of three years and an exercise price equal to the market value per share of common stock on February 28, 2013. The
(0)
(0)CASI Pharmaceuticals, Inc. (CASI) Stock Research Links
Scroll down for more posts ▼